Deal History
About us
The Company
Team
Offices
Globalscope
Worldwide
Canada
Denmark
France
Germany
Poland
Sweden
United Kingdom
USA
Services
Corporate Finance
Debt Advisory
Equity Research
Growth Equity Financing
IPO Strategy & Preparation
Industries
Business Services
Consumer & Internet
Industrial Technology
Life Science
Software & TMT
Energy & Infrastructure
Research
Equity Research
Macro and Markets
Career
Events
Insights
News
Company News
Deal News
In the Media
Newsletter
Contact
Newsletter
INT
DA
DE
FR
SV
US
Main menu button
Team
Deals
Contact
Team
Deals
Contact
News
All
Abera Bioscience
Adventure Box
Adverty
All for One Group
ALM Equity
Alzecure Pharma
Arctic Minerals
Biosergen
Candles Scandinavia
Carlsquare
CDON
CellaVision
CSAM Health Group
DanCann Pharma
Ecoclime
Elicera Therapeutics
Enrad
Frequentis
FRISQ
Future Gaming
GHP Specialty Care
GIAB
H&D Wireless
Hanza
Herantis Pharma
Immunovia
InCoax
Kancera
KlaraBo
Lohilo Foods
Lokotech
Medclair Invest
Midsummer
Mindark PE
Modus Therapeutics
Moninvent
NeoDynamics
Nischer Properties
Nosa Plugs
Observit
Orion Corporation
Pharmiva
Raytelligence
Risk Intelligence
SBB i Norden
Sensec
Spotlight Group
Svenska Aerogel
Teneo AI
Thinc Collective
Viva Wine Group
Ytrade Group
Zazz Energy
Zinzino
All
Company News
Deal News
Equity Research
Events
In the Media
Insights
Macro and Markets
19 May 2025
Equity Research Svenska Aerogel, Q1 2025: Strong pipeline and growth
Equity Research
Svenska Aerogel
08 May 2025
Equity Research Svenska Aerogel, Q1 2025: Higher than expected revenues and costs
Equity Research
Svenska Aerogel
07 Mar 2025
Equity Research Svenska Aerogel, Q4 2024: Growing n.o customers and share issue in Q2
Equity Research
Svenska Aerogel
27 Feb 2025
Equity Research Svenska Aerogel, Q4 2024: Higher than expected revenues and rights issue
Equity Research
Svenska Aerogel
05 Dec 2024
Equity Research Svenska Aerogel, Q3 2024: Supplier agreements could boost revenues
Equity Research
Svenska Aerogel
20 Nov 2024
Equity Research Svenska Aerogel, Q3 2024: Lower than expected costs
Equity Research
Svenska Aerogel
09 Sep 2024
Equity Research Svenska Aerogel, Q2 2024: Low revenues, but important orders in place
Equity Research
Svenska Aerogel
29 Aug 2024
Equity Research Svenska Aerogel, Q2 2024: Net revenues below expectations, but better profitability
Equity Research
Svenska Aerogel
20 Jun 2024
Equity research Svenska Aerogel: New pilot orders and improved finances
Equity Research
Svenska Aerogel
08 May 2024
Equity Research Svenska Aerogel, Q1 2024: Streamlining to reduce costs
Equity Research
Svenska Aerogel
03 May 2024
Equity Research Svenska Aerogel, Q1 2024: Increasing effectivity and pilot order from key client
Equity Research
Svenska Aerogel
15 Apr 2024
Equity Research, Svenska Aerogel: Savings provide improved share price potential
Equity Research
Svenska Aerogel
03 Apr 2024
Equity Research Svenska Aerogel, Q4 2023: Improved production facilities to boost margins
Equity Research
Svenska Aerogel
15 Mar 2024
Equity Research Svenska Aerogel, Q4 2023: Increased sales of Quartzene™ and lower than expected costs
Equity Research
Svenska Aerogel
19 Dec 2023
Equity Research Svenska Aerogel: Share issue to fuel growth
Equity Research
Svenska Aerogel
06 Dec 2023
Equity Research Update Svenska Aerogel, Q3 2023: Accelerating order intake and new supplier deal
Equity Research
Svenska Aerogel
24 Nov 2023
Equity Research Svenska Aerogel, first impression Q3 2023: Revenues still at low levels, but promising order intake
Equity Research
Svenska Aerogel
15 Nov 2023
MrktBUZZ Svenska Aerogel: Major order received - with further potential
Equity Research
Svenska Aerogel
30 Aug 2023
Equity Research Svenska Aerogel, Q2 2023: Lower than expected revenues but positive development with key customers
Equity Research
Svenska Aerogel
24 Jul 2023
Mrkt BUZZ Svenska Aerogel: Key Clients Introduce Quartzene in Products
Equity Research
Svenska Aerogel
1
2